Astellas has options for exclusive licenses on two other gene therapy candidates after investing $50 million to take a 15% stake in their developer, Dallas-based Taysha Gene Therapies—Taysha’s ...

Astellas Gene Therapies will integrate approximately 350 current employees from Audentes including all corporate functions, which will continue to provide support to the Gene Therapy Center of ...

Shares of Taysha Gene Therapies (NASDAQ: TSHA) have fallen by 85% since the September 2020 IPO was priced at $20. Performance is an even more brutal -88% since my initial article was published in ...

Astellas CEO Q&A (Part 1): There Is No Playbook on Cell and Gene Therapies A Q&A with Naoki Okamura revealed that when it comes to cell and gene therapies, the CEO of Astellas Pharma believes risk ...

Astellas Gene Therapies signaled plans to further expand in its namesake focus area when it joined Taysha Gene Therapies (TSHA) this week to announce a $50 million investment in the Dallas drug ...

About Astellas Gene Therapies Astellas integrated its wholly owned subsidiary, Audentes Therapeutics, Inc. as of April 1, 2021 and established "Astellas Gene Therapies" within the organization as ...

Astellas Gene Therapies is based in South San Francisco, with manufacturing and laboratory facilities in South San Francisco, Calif., Sanford, N.C. and Tsukuba, Japan.

Gene Therapies Center of Excellence focuses on AAV The new operation is part of the Astellas Gene Therapies Center of Excellence that was created following the 2020 acquisition of San Francisco ...

Astellas’s trial holds are not outliers. Many biotech companies have had gene therapy clinical research temporarily halted as complications arise and the FDA asks questions. In some cases, the ...

Astellas’ gene therapy strategy is sinking deeper into the mire. Having reviewed the data on its Duchenne muscular dystrophy (DMD) gene therapies, the Japanese drugmaker has decided to scrap the ...

Kenji Yasukawa, Ph.D., the new Astellas CEO, pledged to push the Japanese drugmaker further into gene and cell therapies for ocular, oncology and other diseases. Now the company says it will ...

Global pharmaceutical firm Astellas, which operates a $100 million gene therapy manufacturing plant in Sanford, is investing $50 million in San Diego-based Poseida Therapeutics.